Sandoz wins Health Canada approval for generic semaglutide injection
Health Canada granted marketing authorization for Sandoz Semaglutide, a generic version of Novo Nordisk’s Ozempic. Approval covers once-weekly subcutaneous use in adults with type 2 diabetes to improve glycemic control. Product set to launch in three dose strengths via two pen presentations. Sandoz sees no material 202